Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease

doi:10.3748/wjg.v27.i10.959

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (14216)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

805

WORD

282

HTML

10924

Figures (1-2)

289

Tables (1-4)

225

Sum=12525

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

557

Download

1134

Sum=1691

Mar 14, 2021 (publication date) through Apr 26, 2024

Times Cited of This Article

Times Cited (31)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastroenterol. Mar 14, 2021; 27(10): 959-975
Published online Mar 14, 2021. doi: 10.3748/wjg.v27.i10.959

Table 2 Changes in clinical variables and liver function tests from baseline during the trial

Parameter	Baseline	3 mo	6 mo
Weight (total sample), kg	94.8 (86.7; 102.1)	93.0 (86.0; 100.0)^c	92.9 (85.0; 98.3)^c
Men	95.0 (92.0; 104.2)	94.0 (90; 101.1)^c	93.7 (88.7; 100.0)^c
Women	86.7 (82.0; 96.0)	85.0 (80.0; 94.8)^c	85.0 (79.0; 95.0)^b
∆ total sample, kg		-1.0 (-2.4; 0.0)	-1.0 (-2.4; 0.0)
Weight loss > 5% (total sample)		11 (6.3)	54 (31)^c
Men		8 (6.6)	39 (32.2)^c
Women		3 (5.6)	15 (28.3)^b
BMI (total sample), kg/m²	31.2 (29.4; 34.0)	30.9 (29.3; 33.3)^c	30.6 (29.0; 33.1)^c
Men	30.7 (29.0; 33.3)	30.4 (29.0; 32.6)^c	30.1 (28.4; 32)^c
Women	32.0 (30.7; 36.2)	31.5 (30.1; 34.6)^c	31.6 (29.7; 34.4)^b
∆ total sample, kg/m²		-0.4 (-0.9; 0.0)	-0.3 (-0.8; 0.0)
Waist circumference (total sample), cm	102.0 (97.0; 111.8)	100.0 (96.0; 108.0)^c	100.0 (94.0; 106.0)^c
Men	103.0 (98.0; 112.0)	102.0 (97.0; 110.0)^c	100 (97.0; 106.0)^c
Women	99.0 (93.0; 106.0)	98.0 (92.0; 105.0)^c	97.0 (90.0; 102.0)^c
∆ total sample, сm		-2.0 (-3.0; 0.0)	0.0 (-2.0; 0.0)^c
ALT (total sample), U/L	53.0 (34.0; 78.0)	35.0 (26.0; 45.0)^c	29.0 (24.0; 38.0)^c
Men	55.8 (37.0; 78.0)	38.0 (29.0; 46.0)^c	32.0 (25.9; 41.0)^c
Women	44.0 (30.8; 69.0)	28.5 (21.6; 38.0)^c	26.0 (16.5; 33.2)^c
∆ total sample, U/L		-14.1 (-31.0; -5.3)	-6.5 (-14.0; 0.1)^c
ALT (total sample) 10-19.9/20-39.9/≥ 40 U/L	5 (2.8)/53 (30.5)/116 (66.7)	15 (8.6)/95 (54.6)/64(36.8)^b	26 (14.9)/108 (62.1)/40 (23.0)^c
Men	1 (0.8)/35 (28.9)/85 (70.2)	5 (4.1)/64 (52.9)/52 (43)^c	10 (8.3)/79 (65.3)/32 (26.4)^a
Women	4 (7.5)/18 (34)/31 (58.5)	10 (18.9)/31 (58.5)/12 (22.6)^c	16 (30.2)/29 (54.7)/8 (15.1)
AST (total sample), U/L	31.0 (24.0; 42.0)	26.5 (21.0; 34.0)^c	25.0 (21.0; 29.0)^c
Men	29.1 (23.5; 42.0)	26.0 (21.0; 33.0)^c	25.0 (21.0; 28.0)^c
Women	32.0 (24.0; 42.0)	28.0 (22.0; 35.0)^c	26.0 (23.0; 32.0)
∆ total sample, U/L		-4.0 (-12.0; 1.0)	-2.0 (-7.0; 2.2)^b
GGT (total sample), U/L	36.0 (26.0; 48.0)	28.0 (21.0; 38.0)^c	26.0 (19.0; 35.0)^c
Men	36.0 (28.0; 46.0)	31.0 (24.0; 41.0)^c	26.0 (21.0; 35.0)^c
Women	35.0 (23.0; 53.0)	23.0 (18.0; 30.0)^c	21.0 (12.0; 34.0)
∆ total sample, U/L		-5.0 (-15.0; 2.0)	-3.0 (-8.0; 2.0)^c

^aP < 0.05.

^bP < 0.01.

^cP < 0.001. Data are presented as median (IQR) or n (%). BMI: Body mass index; ALT: Alanine aminotransferase; AST: Aspartate transaminase; GGT: Glutamyltransferase.

Citation: Nadinskaia M, Maevskaya M, Ivashkin V, Kodzoeva Kh, Pirogova I, Chesnokov E, Nersesov A, Kaibullayeva J, Konysbekova A, Raissova A, Khamrabaeva F, Zueva E. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2021; 27(10): 959-975
URL: https://www.wjgnet.com/1007-9327/full/v27/i10/959.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i10.959